Lead Product(s) : Varlitinib
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 11, 2017
Lead Product(s) : Varlitinib
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 27, 2017
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2017
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2017
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Biorasi | CMIC Co, Ltd. Japan | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 28, 2017
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Biorasi | CMIC Co, Ltd. Japan | Syneos Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2017
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2016
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2016
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2015
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : ASLAN Pharmaceuticals | National Medical Research Council, Singapore
Deal Size : Inapplicable
Deal Type : Inapplicable
ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2015
Lead Product(s) : Varlitinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : ASLAN Pharmaceuticals | National Medical Research Council, Singapore
Deal Size : Inapplicable
Deal Type : Inapplicable